The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma

Anticancer Research

Volumn 19, Issue 4 A, 1999, Pages 2599-2601

  Oremek, G M ^a,f   Teigelkamp, S ^b   Kramer, W ^c   Eigenbrodt, E ^d   Usadel, K H ^e  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b ScheBo Tech GmbH   (Germany)

^c Urologische Klinik   (Germany)

^d JUSTUS LIEBIG UNIVERSITY   (Germany)

^e Medizinische Klinik II   (Germany)

^f GOETHE UNIVERSITY   (Germany)

Author keywords

Pyruvate kinase isoenzyme Tu M2 PK; Renal carcinoma

Indexed keywords

PYRUVATE KINASE; TUMOR MARKER;

BODY FLUID; CONFERENCE PAPER; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; NEPHRITIS; PRIORITY JOURNAL;

CARCINOMA, RENAL CELL; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; ISOENZYMES; KIDNEY NEOPLASMS; NEOPLASM STAGING; NEPHRITIS; PYRUVATE KINASE; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0032780468     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Board M, Humm S and Newsholme EA: Maximum Activities of Key Enzymes of Glycolysis, Glutaminolysis, Pentose Phosphate Pathway and Tricarboxylic Acid Cyclein Normal, Neoplastic and Suppressed Cells. Biochem J 265:503-509 1990.
2. Brinck U, Eigenbrodt E., Oehmke M, Mazurek S and Fischer G: L- and M2- Pyruvate Kinase Expression in Renal Cell Carcinomas and their Metastases. Virch Arch 424: 177-185, 1994.
3. Eigenbrodt E, Reinacher M, Scheefers-Borchel U, Scheefers H and Friis R: Double Role for Pyruvate Kinase Type M2 in Expansion of Phosphometabolite Pools Found in Tumor Cells. Critical Reviews in Oncogenesis 3 (1,2): 9-115, 1992.
4. Eigenbrodt E, Gerbracht U, Mazurek S, Presck P and Friis R: Carbohydrate Metabolism and Neoplasia: New Perspectives for Diagnosis and Therapy. In Biochemical and Molecular Aspects of Selected Cancers, Vol. II, T.G. Pretlow and T.P. Pretlow (ed.), Academic Press Inc, New York, pp. 311-385, 1994.
5. Eigenbrodt E, Basenau D, Holthusen S, Mazurek S and Fischer G: Quantification of Tumor Type M2 Pyruvate Kinase (Tu M2-PK) in Human Carcinomas. Anticancer Res 17: 3153-5156, 1997.
6. Fateh-Moghadam A and Stieber P: Tumormarker und ihr sinnvoller Einsatz. Jürgen Hartmann Verlag GmbH, Marloffstein-Rathsberg, 1993.
7. Fischer G, Holzrichter S, Reinacher M, Heinrichs M. Dembowski J. und Eigenbrodt E: Immunhistochemische Darstellung der L- und M2-Pyruvatkinase in primären Nierenzellkarzinomen und deren Metastasen. Verh Dtsch Ges Path 73: 422-427, 1989.
8. Ibsen KH, Orlando RA, Garrat KN, Hernandez AN, Giorlando S and Nungaray G: Expression of Multimolecular Forms of Pyruvate Kinase in Normal, Benign, and Malignant Human Breast Tissue. Cancer Res 42: 888-892, 1982.
9. Lüthgens K: Indikationsgebiete für Tumormarker. Clin Lab 41: 567-572, 1995
10. Oremek GM, Eigenbrodt E, Rädle J, Zeuzem S and Seiffert UB: Value of the Serum Levels of the Tumor Marker Tu M2-PK in Pancreatic Cancer. Anticancer Res 17: 3031-3034, 1997.
11. Robson CJ, Churchill BM and Anderson W: The Results of Radical Nephrectomy for Renal Cell Carcinoma. J Urol 101: 297-301, 1969.
12. Scheefers-Borchel U, Scheefers H, Michel A, Will H, Fischer G, Basenau D, Dahlmann N, Laumen R, Mazurek S, Eigenbrodt E: Quantitative determination (ELISA) of pyruvate kinase type tumor M2. in Current Tumor Diagnosis, Applications, Clinical Relevance, Research-trends. R. Klapdor (ed.), W. Zuckschwerdt Verlag GmbH, München, pp. 365-368, 1994.